In silico drug discovery services market is likely to be worth USD 124 million by 2030, growing at a
Excessive capital requirement and myriad of other complexities associated with the discovery of biologics have prompted drug developers to adopt in silico tools / techniques to expedite the discovery timelines
Roots Analysis is pleased to announce the publication of its recent study, titled, “In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery / Multi-Target Drug Design, Interface Based Drug Discovery, Approaches).”
The report features an extensive study on the current landscape and the likely future potential of the companies offering services for the discovery of large molecule drugs based on the use of in silico tools and techniques. The study features an in-depth analysis, highlighting the capabilities of various industry stakeholders. In addition to other elements, the report includes:
A detailed assessment of the current market landscape of companies offering in silico drug discovery services for large molecules.
Elaborate profiles of key industry players that offer a wide range of in silico drug discovery services (shortlisted on the basis of the company size).
A detailed peer group-based benchmarking analysis, comparing the involved players based on several relevant parameters related to company and services.
An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain.
A detailed analysis assessing the current opportunity within in silico drug discovery services market.
A discussion on the various business strategies that can be adopted by in silico drug discovery service providers in order to maintain a competitive edge in this industry.